CHMP5 and COVID-19: Likewise, in a subgroup of patients (n = 36, 13.6%) in whom SARS-CoV-2 anti-Spike antibody titer was measured post-PrEP, a significantly lower antibody titer was seen in COVID-19 patients (n = 10) compared to non-infected patients (n = 26): 1261.6 (857.7–1835.1) vs. 2201.7 (1380.4–3405.7) BAU/mL (p = 0.0185) (Table 6).